NASDAQ
6.54USD
+0.13 (+2.03%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
143.1M
P/E
—
EPS
—
Beta
3.81
52W range
3.35-17.94
Day range
6.17–6.82
Open
6.58
Prev close
6.41
Volume
66.3K
Avg volume
231.5K
Dividend
0.00
IPO
2025-02-13
https://www.businesswire.com/news/home/20260814973459/en/Stockholder-Alert-Robbins-LLP-Informs-Investors-of-the-Aardvark-Therapeutics-Inc.-UWM-Class-Action/ · 8/14/2026-0.80
https://www.prnewswire.com/news-releases/investor-alert-the-hub-group-inc-nasdaq-hubg-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit--hbss-302831752.html · 7/22/2026-1.00
https://www.globenewswire.com/news-release/2026/06/02/3305652/1087/en/INVESTOR-ALERT-Pomerantz-Law-Firm-Investigates-Claims-On-Behalf-of-Investors-of-Doximity-Inc-DOCS.html · 6/2/2026-0.80
https://www.globenewswire.com/news-release/2026/06/02/3305654/1087/en/INVESTOR-ALERT-Pomerantz-Law-Firm-Investigates-Claims-On-Behalf-of-Investors-of-Intuit-Inc-INTU.html · 6/2/2026-0.80
https://www.globenewswire.com/news-release/2026/05/26/3301504/1087/en/INVESTOR-ALERT-Pomerantz-Law-Firm-Investigates-Claims-On-Behalf-of-Investors-of-York-Space-Systems-Inc-YSS.html · 5/26/2026-0.50
https://www.globenewswire.com/news-release/2026/05/26/3301501/1087/en/INVESTOR-ALERT-Pomerantz-Law-Firm-Investigates-Claims-On-Behalf-of-Investors-of-Sigma-Lithium-Corporation-SGML.html · 5/26/2026-0.80
https://www.globenewswire.com/news-release/2026/04/28/3282993/32716/en/Aardvark-Therapeutics-AARD-Faces-Investor-Scrutiny-Amid-56-Drop-On-Clinical-Pause-For-Lead-Drug-Candidate-Hagens-Berman.html · 4/28/2026-1.00
https://www.prnewswire.com/news-releases/apo-investor-alert-apollo-global-management-inc-securities-class-action---investors-with-losses-may-seek-to-lead-the-lawsuit-after-claims-black-concealed-epstein-payments--hagens-berman-302748969.html · 4/21/2026-1.00
https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-weis-markets-inc---wmk-302744250.html · 4/16/2026-1.00
https://www.globenewswire.com/news-release/2026/04/14/3273769/32716/en/Aardvark-Therapeutics-AARD-Faces-Investor-Scrutiny-Amid-56-Drop-On-Clinical-Pause-For-Lead-Drug-Candidate-Hagens-Berman.html · 4/14/2026-1.00
https://www.globenewswire.com/news-release/2026/04/09/3271484/32716/en/Aardvark-Therapeutics-AARD-Faces-Investor-Scrutiny-Amid-56-Drop-On-Clinical-Pause-For-Lead-Drug-Candidate-Hagens-Berman.html · 4/9/2026-1.00
https://www.prnewswire.com/news-releases/corcept-therapeutics-cort-litigation-hagens-berman-alerts-corcept-cort-investors-to-securities-class-action-and-april-21-lead-plaintiff-deadline-302712765.html · 3/12/2026-1.00
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
